World Journal of Surgery

, Volume 35, Issue 1, pp 147–153

Parathyroid Carcinoma Encountered After Minimally Invasive Focused Parathyroidectomy may not Require Further Radical Surgery

  • Christine J. O’Neill
  • Conan Chan
  • James Symons
  • Diana L. Learoyd
  • Stan B. Sidhu
  • Leigh W. Delbridge
  • Anthony Gill
  • Mark S. Sywak
Article

Abstract

Background

Parathyroid carcinoma accounts for <1% of tumors in primary hyperparathyroidism (PHPT). Distinguishing parathyroid malignancy from benign disease is difficult both before and after initial surgery. Despite the improved specificity of a malignant diagnosis with immunohistochemistry for parafibromin and PGP9.5, proven metastatic behavior remains the gold standard of diagnosis. Minimally invasive focused parathyroidectomy (MIP) is widely performed in patients with PHPT and positive localization studies; thus, it is inevitable that some parathyroid caricnomas will be encountered at MIP. We present our experience of this rare entity.

Methods

The present study represents a surgical case series of patients with parathyroid carcinoma encountered after MIP. The clinicopathological features of benign and malignant parathyroid tumors were compared. Multiple regression analysis was undertaken to compare indicators of malignancy.

Results

Between May 1999 and April 2010, a total of 1,292 patients underwent MIP at the University of Sydney Endocrine Surgical Unit, and a histopathological diagnosis of parathyroid carcinoma was made in seven patients (0.5%). Staining for parafibromin and/or PGP9.5 was abnormal in five carcinomas (71%). Despite subsequent unilateral thyroid lobectomy and lymphadenectomy in six patients, no further malignancy was identified in any specimens. Compared to controls, preoperative calcium (p = 0.04) and parathyroid hormone (p = 0.01) were significantly higher in patients with malignancy. The positive predictive value of these parameters for carcinoma was 56 and 75%, respectively.

Conclusions

In patients diagnosed with parathyroid carcinoma after MIP where preoperative imaging had already demonstrated localized disease, revision en bloc surgery did not reveal any residual disease. The benefits of further radical surgery for parathyroid carcinoma after MIP remain controversial.

References

  1. 1.
    Lee PK, Jarosek SL, Virnig BA et al (2007) Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer 109:1736CrossRefPubMedGoogle Scholar
  2. 2.
    Robert JH, Trombetti A, Garcia A et al (2005) Primary hyperparathyroidism: can parathyroid carcinoma be anticipated on clinical and biochemical grounds? Report of nine cases and review of the literature. Ann Surg Oncol 12:526CrossRefPubMedGoogle Scholar
  3. 3.
    Ippolito G, Palazzo FF, Sebag F et al (2007) Intraoperative diagnosis and treatment of parathyroid cancer and atypical parathyroid adenoma. Br J Surg 94:566CrossRefPubMedGoogle Scholar
  4. 4.
    Bondeson L, Grimelius L, Delellis RA (2004) Parathyroid carcinoma. In: Delellis RA, Lloyd RV, Heitz PU (eds) World Health Organisation classification of tumours, pathology and genetics: tumour of endocrine organs. IARC Press, Lyon, p 124Google Scholar
  5. 5.
    Sandelin K, Tullgren O, Farnebo LO (1994) Clinical course of metastatic parathyroid cancer. World J Surg 18:594CrossRefPubMedGoogle Scholar
  6. 6.
    Shattuck TM, Valimaki S, Obara T et al (2003) Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 349:1722CrossRefPubMedGoogle Scholar
  7. 7.
    Howell VM, Haven CJ, Kahnoski K et al (2003) HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J Med Genet 40:657 [Erratum appears in J Med Genet 41(1):20, 2004]Google Scholar
  8. 8.
    Cetani F, Pardi E, Borsari S et al (2004) Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J Clin Endocrinol Metab 89:5583CrossRefPubMedGoogle Scholar
  9. 9.
    Krebs LJ, Shattuck TM, Arnold A (2005) HRPT2 mutational analysis of typical sporadic parathyroid adenomas. J Clin Endocrinol Metab 90:5015CrossRefPubMedGoogle Scholar
  10. 10.
    Sarquis MS, Silveira LG, Pimenta FJ et al (2008) Familial hyperparathyroidism: surgical outcome after 30 years of follow-up in three families with germline HRPT2 mutations. Surgery 143:630CrossRefPubMedGoogle Scholar
  11. 11.
    Haven CJ, Howell VM, Eilers PH et al (2004) Gene expression of parathyroid tumors: molecular subclassification and identification of the potential malignant phenotype. Cancer Res 64:7405CrossRefPubMedGoogle Scholar
  12. 12.
    Howell VM, Gill A, Clarkson A et al (2009) Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma. J Clin Endocrinol Metab 94:434CrossRefPubMedGoogle Scholar
  13. 13.
    Sackett WR, Barraclough B, Reeve TS et al (2002) Worldwide trends in the surgical treatment of primary hyperparathyroidism in the era of minimally invasive parathyroidectomy. Arch Surg 137:1055CrossRefPubMedGoogle Scholar
  14. 14.
    Pang T, Stalberg P, Sidhu S et al (2007) Minimally invasive parathyroidectomy using the lateral focused mini-incision technique without intraoperative parathyroid hormone monitoring. Br J Surg 94:315CrossRefPubMedGoogle Scholar
  15. 15.
    Slepavicius A, Beisa V, Janusonis V et al (2008) Focused versus conventional parathyroidectomy for primary hyperparathyroidism: a prospective, randomized, blinded trial. Langenbecks Arch Surg 393:659CrossRefPubMedGoogle Scholar
  16. 16.
    McGill J, Sturgeon C, Kaplan SP et al (2008) How does the operative strategy for primary hyperparathyroidism impact the findings and cure rate? A comparison of 800 parathyroidectomies. J Am Coll Surg 207:246CrossRefPubMedGoogle Scholar
  17. 17.
    Gill AJ, Clarkson A, Gimm O et al (2006) Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol 30:1140PubMedGoogle Scholar
  18. 18.
    Obara T, Okamoto T, Kanbe M et al (1997) Functioning parathyroid carcinoma: clinicopathologic features and rational treatment. Semin Surg Oncol 13:134CrossRefPubMedGoogle Scholar
  19. 19.
    Hakaim AG, Esselstyn CB Jr (1993) Parathyroid carcinoma: 50-year experience at The Cleveland Clinic Foundation. Cleve Clin J Med 60:331PubMedGoogle Scholar
  20. 20.
    Wynne AG, van Heerden J, Carney JA et al (1992) Parathyroid carcinoma: clinical and pathologic features in 43 patients. Medicine 71:197CrossRefPubMedGoogle Scholar
  21. 21.
    Shortell CK, Andrus CH, Phillips CE Jr et al (1991) Carcinoma of the parathyroid gland: a 30-year experience. Surgery 110:704PubMedGoogle Scholar
  22. 22.
    Obara T, Fujimoto Y (1991) Diagnosis and treatment of patients with parathyroid carcinoma: an update and review. World J Surg 15:738CrossRefPubMedGoogle Scholar
  23. 23.
    Iihara M, Okamoto T, Suzuki R et al (2007) Functional parathyroid carcinoma: long-term treatment outcome and risk factor analysis. Surgery 142:936 [Erratum appears in Surgery 143:302, 2008]Google Scholar
  24. 24.
    Busaidy NL, Jimenez C, Habra MA et al (2004) Parathyroid carcinoma: a 22-year experience. Head Neck 26:716CrossRefPubMedGoogle Scholar
  25. 25.
    Anderson BJ, Samaan NA, Vassilopoulou-Sellin R et al (1983) Parathyroid carcinoma: features and difficulties in diagnosis and management. Surgery 94:906PubMedGoogle Scholar
  26. 26.
    Sandelin K, Auer G, Bondeson L et al (1992) Prognostic factors in parathyroid cancer: a review of 95 cases. World J Surg 16:724CrossRefPubMedGoogle Scholar
  27. 27.
    Hundahl SA, Fleming ID, Fremgen AM et al (1999) Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985–1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 86:538CrossRefPubMedGoogle Scholar
  28. 28.
    Enomoto K, Uchino S, Ito A et al (2010) The surgical strategy and the molecular analysis of patients with parathyroid cancer. World J Surg 34:2604–2610CrossRefPubMedGoogle Scholar
  29. 29.
    Biskobing DM (2010) Significance of elevated parathyroid hormone after parathyroidectomy. Endocr Pract 16:112–117CrossRefPubMedGoogle Scholar
  30. 30.
    Shane E (2001) Clinical review 122: parathyroid carcinoma. J Clin Endocrinol Metab 86:485–493CrossRefPubMedGoogle Scholar
  31. 31.
    Ishida T, Yokoe T, Izuo M (1991) Nationwide surgery of parathyroid operations in Japan (1980–1989). Endocr Surg (Tokyo) 8:37Google Scholar
  32. 32.
    Favia G, Lumachi F, Polistina F et al (1998) Parathyroid carcinoma: sixteen new cases and suggestions for correct management. World J Surg 22:1225CrossRefPubMedGoogle Scholar
  33. 33.
    Fujimoto Y, Obara T, Ito Y et al (1986) Localization and surgical resection of metastatic parathyroid carcinoma. World J Surg 10:539CrossRefPubMedGoogle Scholar
  34. 34.
    Rawat N, Khetan N, Williams DW et al (2005) Parathyroid carcinoma. Br J Surg 92:1345CrossRefPubMedGoogle Scholar
  35. 35.
    Kebebew E (2001) Parathyroid carcinoma. Curr Treat Options Oncol 2:347CrossRefPubMedGoogle Scholar
  36. 36.
    Kebebew E, Arici C, Duh QY et al (2001) Localization and reoperation results for persistent and recurrent parathyroid carcinoma. Arch Surg 136:878CrossRefPubMedGoogle Scholar
  37. 37.
    McCance DR, Kenny BD, Sloan JM et al (1987) Parathyroid carcinoma: a review. J R Soc Med 80:505PubMedGoogle Scholar
  38. 38.
    Rao SR, Shaha AR, Singh B et al (2002) Management of cancer of the parathyroid. Acta Otolaryngol 122:448CrossRefPubMedGoogle Scholar
  39. 39.
    Clayman GL, Gonzalez HE, El-Naggar A et al (2004) Parathyroid carcinoma: evaluation and interdisciplinary management. Cancer 100:900CrossRefPubMedGoogle Scholar
  40. 40.
    Munson ND, Foote RL, Northcutt RC et al (2003) Parathyroid carcinoma: is there a role for adjuvant radiation therapy? Cancer 98:2378CrossRefPubMedGoogle Scholar
  41. 41.
    Collins MT, Skarulis MC, Bilezikian JP et al (1998) Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 83:1083CrossRefPubMedGoogle Scholar
  42. 42.
    Silverberg SJ, Rubin MR, Faiman C et al (2007) Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab 92:3803CrossRefPubMedGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2010

Authors and Affiliations

  • Christine J. O’Neill
    • 1
  • Conan Chan
    • 1
  • James Symons
    • 1
  • Diana L. Learoyd
    • 2
  • Stan B. Sidhu
    • 1
  • Leigh W. Delbridge
    • 1
  • Anthony Gill
    • 3
    • 4
  • Mark S. Sywak
    • 1
  1. 1.University of Sydney Endocrine Surgical UnitSt. LeonardsAustralia
  2. 2.Department of EndocrinologyRoyal North Shore HospitalSt. LeonardsAustralia
  3. 3.Department of Anatomical PathologyRoyal North Shore HospitalSt. LeonardsAustralia
  4. 4.University of SydneySydneyAustralia

Personalised recommendations